Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars

Executive Summary

Stakeholders are being asked to respond to a consultation on what steps can be taken to increase the use of biosimilars in Ireland. The generics and biosimilars industry body Medicines for Ireland has welcomed the move but says it has come very late in the day.


Related Content

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps
Delayed Medicines To Hit Irish Market, But Uncertainty Remains For Future
Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars
Ireland Prepares New Biosimilar Policy To Improve Access, Boost Industry





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts